Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001011438-24-000183
Filing Date
2024-02-13
Accepted
2024-02-13 16:27:05
Documents
1
Group Members
AKDL, L.P.CRESTLINE INVESTORS, INC.CRESTLINE MANAGEMENT, L.P.CRESTLINE SI (GP), L.P.

Document Format Files

Seq Description Document Type Size
1 form_sc13ga-denali.htm SC 13G/A 89426
  Complete submission text file 0001011438-24-000183.txt   90934
Mailing Address 201 MAIN STREET SUITE 1900 FORT WORTH TX 76102
Business Address
BRATTON DOUGLAS K (Filed by) CIK: 0001281933 (see all company filings)

Type: SC 13G/A

Mailing Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Business Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 (650) 866-8548
Denali Therapeutics Inc. (Subject) CIK: 0001714899 (see all company filings)

EIN.: 463872213 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A | Act: 34 | File No.: 005-90223 | Film No.: 24626446
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)